JP2010516681A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516681A5
JP2010516681A5 JP2009546439A JP2009546439A JP2010516681A5 JP 2010516681 A5 JP2010516681 A5 JP 2010516681A5 JP 2009546439 A JP2009546439 A JP 2009546439A JP 2009546439 A JP2009546439 A JP 2009546439A JP 2010516681 A5 JP2010516681 A5 JP 2010516681A5
Authority
JP
Japan
Prior art keywords
formula
polymorph
dosage form
solid dosage
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009546439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516681A (ja
JP5468388B2 (ja
Filing date
Publication date
Priority claimed from US11/831,886 external-priority patent/US7378508B2/en
Application filed filed Critical
Publication of JP2010516681A publication Critical patent/JP2010516681A/ja
Publication of JP2010516681A5 publication Critical patent/JP2010516681A5/ja
Application granted granted Critical
Publication of JP5468388B2 publication Critical patent/JP5468388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009546439A 2007-01-22 2008-01-22 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法 Active JP5468388B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US60/881,950 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
US11/831,886 2007-07-31
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013151860A Division JP5764168B2 (ja) 2007-01-22 2013-07-22 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法

Publications (3)

Publication Number Publication Date
JP2010516681A JP2010516681A (ja) 2010-05-20
JP2010516681A5 true JP2010516681A5 (enExample) 2011-03-10
JP5468388B2 JP5468388B2 (ja) 2014-04-09

Family

ID=38661942

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546439A Active JP5468388B2 (ja) 2007-01-22 2008-01-22 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法
JP2013151860A Active JP5764168B2 (ja) 2007-01-22 2013-07-22 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013151860A Active JP5764168B2 (ja) 2007-01-22 2013-07-22 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法

Country Status (23)

Country Link
US (5) US7378508B2 (enExample)
EP (3) EP3412678B1 (enExample)
JP (2) JP5468388B2 (enExample)
KR (2) KR20090117924A (enExample)
CN (2) CN102746353A (enExample)
BR (1) BRPI0806878A2 (enExample)
CA (2) CA2676061C (enExample)
CY (1) CY1120358T1 (enExample)
DK (1) DK2125850T3 (enExample)
ES (2) ES2676308T3 (enExample)
HR (1) HRP20180912T1 (enExample)
HU (2) HUE039395T2 (enExample)
IL (2) IL199984A0 (enExample)
LT (1) LT2125850T (enExample)
MX (2) MX2009007730A (enExample)
NZ (2) NZ578697A (enExample)
PL (2) PL2125850T3 (enExample)
PT (2) PT2125850T (enExample)
RU (1) RU2478643C2 (enExample)
SI (1) SI2125850T1 (enExample)
TR (1) TR201810589T4 (enExample)
TW (2) TWI425942B (enExample)
WO (1) WO2008091554A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
HUE031581T2 (en) * 2004-05-14 2017-07-28 Merck Sharp & Dohme Treatment of diseases associated with the use of antibiotics
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
EA027622B1 (ru) * 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
MX2012013372A (es) * 2010-05-18 2013-05-01 Optimer Pharmaceuticals Inc Metodos para tratar infecciones bacterianas recurrentes.
US20140024609A1 (en) * 2011-02-04 2014-01-23 Optimer Pharmaceuticals ,Inc. Treatment of Bacterial Infections
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US8722863B2 (en) * 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN105142612A (zh) 2013-03-08 2015-12-09 奇普拉股份有限公司 用于直肠给药的药物组合物
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
CA2940433A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. Process for preparing novel forms of tiacumicin b
CA2940902C (en) * 2014-03-18 2022-10-25 Xellia Pharmaceuticals Aps Polymorphs and solid states of tiacumicin b
CA2948400A1 (en) 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
WO2015175695A1 (en) * 2014-05-13 2015-11-19 Debrabander Jef Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
EA034885B1 (ru) 2015-07-03 2020-04-02 Астеллас Фарма Юэроп Лтд. Новая схема лечения тиакумициновым соединением
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321362A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company De(mycinosyloxy)tylosin and process for its production
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
DK1652926T3 (da) 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
HUE031581T2 (en) * 2004-05-14 2017-07-28 Merck Sharp & Dohme Treatment of diseases associated with the use of antibiotics
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
CN102614207B (zh) 2005-01-31 2016-01-13 默克夏普&多梅有限公司 18元环大环化合物及其类似物
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CN102503994A (zh) 2005-10-21 2012-06-20 奥普蒂姆药物公司 治疗艰难梭菌相关的腹泻的方法
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Similar Documents

Publication Publication Date Title
JP2010516681A5 (enExample)
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
JP2014501282A5 (enExample)
JP2013516473A5 (enExample)
RU2466129C2 (ru) Твердые формы рацемического илапразола
JP2018024682A5 (enExample)
WO2016025720A1 (en) Solid state forms of ibrutinib
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
JP2012508178A5 (enExample)
JP2011518833A5 (enExample)
RU2015143643A (ru) Соль омекамтива мекарбила и способ ее получения
JP2013538849A5 (enExample)
JP2016510768A5 (enExample)
JP2009521414A5 (enExample)
JP2010539237A5 (enExample)
RU2019112080A (ru) Соли производного индазола и их кристаллы
HRP20230813T1 (hr) Upadacitinib solni spoj i postupak njegove pripreme
JP2012532106A5 (enExample)
JP2016537326A5 (enExample)
JP2011529942A5 (enExample)
EA028171B1 (ru) Способ получения высокочистой калиевой соли азилсартана медоксомила
JP2016512518A (ja) ベムラフェニブ塩酸塩の固体形態
CN102875634A (zh) 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
WO2016016774A1 (en) Crystalline forms of canagliflozin
JP2022553833A5 (enExample)